Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of $163.69 billion. The enterprise value is $215.47 billion.
| Market Cap | 163.69B |
| Enterprise Value | 215.47B |
Important Dates
The next confirmed earnings date is Tuesday, November 3, 2026, before market open.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | Jul 24, 2026 |
Share Statistics
Pfizer has 5.70 billion shares outstanding. The number of shares has increased by 0.34% in one year.
| Current Share Class | 5.70B |
| Shares Outstanding | 5.70B |
| Shares Change (YoY) | +0.34% |
| Shares Change (QoQ) | -0.56% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 68.26% |
| Float | 5.69B |
Valuation Ratios
The trailing PE ratio is 37.75 and the forward PE ratio is 10.37.
| PE Ratio | 37.75 |
| Forward PE | 10.37 |
| PS Ratio | 2.57 |
| Forward PS | 2.68 |
| PB Ratio | 1.92 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.90 |
| P/OCF Ratio | 12.22 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.49, with an EV/FCF ratio of 19.61.
| EV / Earnings | 49.72 |
| EV / Sales | 3.38 |
| EV / EBITDA | 8.49 |
| EV / EBIT | 11.43 |
| EV / FCF | 19.61 |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.74.
| Current Ratio | 1.27 |
| Quick Ratio | 0.85 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | 2.41 |
| Debt / FCF | 5.78 |
| Interest Coverage | 6.98 |
Financial Efficiency
Return on equity (ROE) is 5.01% and return on invested capital (ROIC) is 13.49%.
| Return on Equity (ROE) | 5.01% |
| Return on Assets (ROA) | 5.78% |
| Return on Invested Capital (ROIC) | 13.49% |
| Return on Capital Employed (ROCE) | 11.18% |
| Weighted Average Cost of Capital (WACC) | 5.19% |
| Revenue Per Employee | $849,280 |
| Profits Per Employee | $57,787 |
| Employee Count | 75,000 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.49 |
Taxes
| Income Tax | -164.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.88% in the last 52 weeks. The beta is 0.30, so Pfizer's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +20.88% |
| 50-Day Moving Average | 27.14 |
| 200-Day Moving Average | 26.37 |
| Relative Strength Index (RSI) | 66.65 |
| Average Volume (20 Days) | 31,873,640 |
Short Selling Information
The latest short interest is 155.20 million, so 2.72% of the outstanding shares have been sold short.
| Short Interest | 155.20M |
| Short Previous Month | 149.27M |
| Short % of Shares Out | 2.72% |
| Short % of Float | 2.73% |
| Short Ratio (days to cover) | 4.64 |
Income Statement
In the last 12 months, Pfizer had revenue of $63.70 billion and earned $4.33 billion in profits. Earnings per share was $0.76.
| Revenue | 63.70B |
| Gross Profit | 47.59B |
| Operating Income | 18.84B |
| Pretax Income | 4.21B |
| Net Income | 4.33B |
| EBITDA | 25.38B |
| EBIT | 18.84B |
| Earnings Per Share (EPS) | $0.76 |
Balance Sheet
The company has $11.70 billion in cash and $63.48 billion in debt, with a net cash position of -$51.78 billion or -$9.08 per share.
| Cash & Cash Equivalents | 11.70B |
| Total Debt | 63.48B |
| Net Cash | -51.78B |
| Net Cash Per Share | -$9.08 |
| Equity (Book Value) | 85.49B |
| Book Value Per Share | 14.95 |
| Working Capital | 8.71B |
Cash Flow
In the last 12 months, operating cash flow was $13.40 billion and capital expenditures -$2.42 billion, giving a free cash flow of $10.99 billion.
| Operating Cash Flow | 13.40B |
| Capital Expenditures | -2.42B |
| Depreciation & Amortization | 6.54B |
| Net Borrowing | 1.78B |
| Free Cash Flow | 10.99B |
| FCF Per Share | $1.93 |
Margins
Gross margin is 74.72%, with operating and profit margins of 29.58% and 6.80%.
| Gross Margin | 74.72% |
| Operating Margin | 29.58% |
| Pretax Margin | 6.61% |
| Profit Margin | 6.80% |
| EBITDA Margin | 39.85% |
| EBIT Margin | 29.58% |
| FCF Margin | 17.25% |
Dividends & Yields
This stock pays an annual dividend of $1.72, which amounts to a dividend yield of 5.99%.
| Dividend Per Share | $1.72 |
| Dividend Yield | 5.99% |
| Dividend Growth (YoY) | 0.58% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 226.35% |
| FCF Payout Ratio | 89.24% |
| Buyback Yield | -0.34% |
| Shareholder Yield | 5.65% |
| Earnings Yield | 2.65% |
| FCF Yield | 6.71% |
Analyst Forecast
The average price target for Pfizer is $28.88, which is 0.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $28.88 |
| Price Target Difference | 0.56% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | -4.17% |
| EPS Growth Forecast (3Y) | -8.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 1, 1999. It was a forward split with a ratio of 3:1.
| Last Split Date | Jul 1, 1999 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Pfizer has an Altman Z-Score of 2.22 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.22 |
| Piotroski F-Score | 7 |